Trial Profile

A Phase II study of TNX-102 for the treatment of agitation in Alzheimer's disease

Status: Planning

Phase of Trial: Phase II

Latest Information Update: 27 Mar 2020

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Cyclobenzaprine (Primary)
Indications Agitation
Focus Registrational; Therapeutic Use
Sponsors Tonix Pharmaceuticals Holding Corp

Most Recent Events

24 Mar 2020 According to a Tonix Pharmaceuticals media release, this study could potentially serve as a pivotal efficacy study to support a New Drug Application (NDA) approval.
13 Aug 2018 According to a Tonix Pharmaceuticals Holding Corp media release, the company has submitted a study protocol to FDA in July 2018 and is waiting for the review and acceptance. This would be the potential pivotal study.
01 May 2018 According to a Tonix Pharmaceuticals media release,t he U.S. Food and Drug Administration (FDA) has cleared Investigational New Drug (IND) application.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com